Zumab. The mixture arm was clearly associated using a longer progression
Chemexpress Zumab. The combination arm was clearly associated with a longer progression cost-free survival (PFS) (4.eight mo vs 2.four mo, P = 0.0016) as well as a greater clinical advantage price…